Table 2.
AGREE II standardized domain scores: CPGs by SEOM (n= 33)
| Guidelines [references] | Domain (%) | Overall score | Recommendation | Qualitya | |||||
|---|---|---|---|---|---|---|---|---|---|
| D1 | D2 | D3 | D4 | D5 | D6 | ||||
| Breast (early stage) [23, 55] | 87.0 | 33.3 | 64.6 | 88.9 | 19.4 | 75.0 | 4.3 | ( +) | high |
| Breast (advanced) [27, 60] | 81.5 | 40.7 | 61.1 | 85.2 | 26.4 | 75.0 | 4.3 | (+ +) | high |
| Breast and ovarian [38, 70] | 90.7 | 53.7 | 59.7 | 90.7 | 16.7 | 77.8 | 5.0 | ( +) | moderate |
| Cervical [29, 82] | 46.3 | 35.2 | 58.3 | 87.0 | 37.5 | 75.0 | 4.7 | (+) | low |
| Colorectal (metastasic) [33, 66] | 98.1 | 44.4 | 79.2 | 100 | 23.6 | 75.0 | 4.7 | (+ +) | high |
| Colorectal (hereditary) [39, 65] | 81.5 | 42.6 | 79.9 | 100 | 54.2 | 75.0 | 5.0 | (+ +) | high |
| Endometrial [25, 57, 58] | 57.4 | 46.3 | 77.8 | 88.9 | 34.7 | 75.0 | 5.7 | (+ +) | high |
| Gastric and gastroesophageal junction [44, 67–69] | 77.8 | 48.1 | 55.6 | 81.5 | 15.3 | 75.0 | 4.3 | ( +) | moderate |
| Gastrointestinal sarcomas [48] | 100.0 | 53.7 | 86.1 | 100 | 48.6 | 75.0 | 4.7 | (+ +) | high |
| Glioblastoma [45] | 92.6 | 63.0 | 77.1 | 100 | 77.8 | 75.0 | 4.7 | (+ +) | high |
| Glioma (anaplasic) [24, 56] | 83.3 | 40.7 | 63.9 | 92.6 | 11.1 | 75.0 | 6.0 | (+ +) | high |
| Glioma (low grade) [54, 83] | 92.6 | 59.3 | 72.2 | 100 | 27.8 | 75.0 | 5.0 | (+ +) | high |
| Head and neck [46, 84, 85] | 75.9 | 53.7 | 70.1 | 100 | 13.9 | 75.0 | 5.3 | ( +) | high |
| Hepatocellular [31, 62, 63] | 90.7 | 63.0 | 76.4 | 98.1 | 31.9 | 75.0 | 5.0 | (+ +) | high |
| Kidney [40, 86–88] | 87.0 | 53.7 | 68.8 | 100 | 45.8 | 75.0 | 6.0 | (+ +) | high |
| Lung (small cell) [30] | 55.6 | 50.0 | 70.8 | 94.4 | 37.5 | 80.6 | 6.0 | ( +) | high |
| Lung (non-small cell) [42, 89] | 72.2 | 44.4 | 68.1 | 96.3 | 19.4 | 75.0 | 4.3 | ( +) | high |
| Lymphoma (follicular non-Hodgkin) [49] | 72.2 | 50.0 | 77.1 | 100 | 15.3 | 75.0 | 5.7 | (+ +) | high |
| Lymphoma (Hodgkin) [52] | 72.2 | 50.0 | 56.3 | 100 | 18.1 | 75.0 | 5.7 | ( +) | moderate |
| Medulloblastoma [41] | 90.7 | 50.0 | 75.0 | 98.1 | 40.3 | 75.0 | 6.0 | (+ +) | high |
| Melanoma [43, 90, 91] | 75.9 | 50.0 | 68.8 | 98.1 | 16.7 | 75.0 | 4.3 | ( +) | high |
| Mesothelioma [47] | 81.5 | 50.0 | 82.6 | 100 | 23.6 | 77.8 | 5.0 | (+ +) | high |
| Nasopharynx [53, 92] | 87.0 | 50.0 | 77.1 | 100 | 19.4 | 75.0 | 4.7 | (+ +) | high |
| Neuroendocrine [37, 93] | 88.9 | 53.7 | 74.3 | 100 | 33.3 | 75.0 | 5.7 | (+ +) | high |
| Ovarian [50, 94, 95] | 96.3 | 53.7 | 81.9 | 94.4 | 33.3 | 77.8 | 5.0 | (+ +) | high |
| Pancreatic and biliary [34, 96, 97] | 79.6 | 50.0 | 63.9 | 98.1 | 36.1 | 75.0 | 5.7 | ( +) | high |
| Prostate [36, 98–100] | 90.7 | 55.6 | 74.3 | 96.3 | 54.2 | 75.0 | 5.7 | (+ +) | high |
| Rectal [26, 59] | 87.0 | 46.3 | 83.3 | 100 | 25.0 | 75.0 | 5.3 | (+ +) | high |
| Sarcoma [28, 61] | 94.4 | 48.1 | 84.0 | 100 | 59.7 | 69.4 | 6.0 | (+ +) | high |
| Testicular [22] | 66.7 | 24.1 | 59.7 | 88.9 | 13.9 | 69.4 | 5.7 | (+) | moderate |
| Thymic epithelial [51] | 92.6 | 51.9 | 80.6 | 100 | 34.7 | 75.0 | 4.3 | (+ +) | high |
| Thyroid [32, 64] | 83.3 | 40.7 | 77.1 | 100 | 45.8 | 72.2 | 5.7 | (+ +) | high |
| Urothelial bladder [35, 101, 102] | 96.3 | 48.1 | 71.5 | 100 | 25.0 | 75.0 | 5.7 | (+) | high |
D1 Scope and purpose, D2 Stakeholder involvement, D3 Rigor of development, D4 Clarity of presentation, D5 Applicability, D6 Editorial independence
aCPGs were considered as “high" quality if they scored ≥ 60% in at least three of six AGREE II domains, including domain 3. If three domains or more were assessed with a score of ≥ 60%, except domain 3, they were considered to be of “moderate” overall quality. CPGs scoring < 60% in two or more domains and < 50% in domain 3 were considered as “low" quality